AR058205A1 - 5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4] tiadiazinas sustituidas - Google Patents
5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4] tiadiazinas sustituidasInfo
- Publication number
- AR058205A1 AR058205A1 ARP060105082A ARP060105082A AR058205A1 AR 058205 A1 AR058205 A1 AR 058205A1 AR P060105082 A ARP060105082 A AR P060105082A AR P060105082 A ARP060105082 A AR P060105082A AR 058205 A1 AR058205 A1 AR 058205A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- naso2a
- so2naa
- so2nha
- nacoa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de la formula (1) en donde R1 es H, A, Hal, OH, OA, SH, SA, SOA, SO2A, NO2, NH2, NHA, NAA', SO2NH2, SO2NHA, SO2NAA', CONH2, CONHA, CONAA', NACOA', NASO2A', COOH, COOA o CN; R2 es H, A, Hal, SO2NH2, SO2NHA, SO2NAA', CONH2, CONHA, CONAA', NACOA', NASO2A', COOH, COOA o CN; R1 y R2 también son juntos metilendioxi; B es NHCOO(CH2)nR3 o NHCO(CH2)nR3; Q está ausente o es alquileno lineal o ramificado C1-4; R3 es R1, Het o alquilo no sustituido o mono-, di-, tri- o tetrasustituido con R4 con 1-6 átomos de C o cicloalquilo C3-8; R4 es A, Hal, OH, OA, SH, SA, SOA, SO2A, NO2, NH2, NHA, NAA', SO2NH2, SO2NHA, SO2NAA', CONH2, CONHA, CONAA', NACOA', NASO2A', COOH, COOA o CN; Het es un heterociclo saturado o aromático mono- o bicíclico con 1 a 4 átomos de N, O y/o , que no está sustituido o que puede estar mono-, di- o trisustituido con R4, CHO, COA, =S, =NH, =NA y/u =O (oxígeno del carbonilo); A, A' son cada uno, de modo independiente entre sí, alquilo no ramificado o ramificado C1-1, en donde 1-7 átomos de H pueden estar reemplazados por F, Cl, y/o Br; cicloalquilo C3-8 o cicloalquilalquileno C4-10; Hal es F, Cl, Br o I; m es 0 o 1; n es 0, 1, 2, o 3; así como sus derivados, solvatos, sales, tautomeros y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores de las tirosina quinasas, en especial de la Met-quinasa, y pueden utilizarse, por ejemplo, para el tratamiento de tumores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005055354A DE102005055354A1 (de) | 2005-11-21 | 2005-11-21 | Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058205A1 true AR058205A1 (es) | 2008-01-23 |
Family
ID=37734761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105082A AR058205A1 (es) | 2005-11-21 | 2006-11-21 | 5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4] tiadiazinas sustituidas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7902186B2 (es) |
| EP (1) | EP1951697B1 (es) |
| JP (1) | JP5334586B2 (es) |
| KR (1) | KR101424825B1 (es) |
| CN (1) | CN101312956A (es) |
| AR (1) | AR058205A1 (es) |
| AT (1) | ATE517878T1 (es) |
| AU (1) | AU2006314873B2 (es) |
| BR (1) | BRPI0618806A2 (es) |
| CA (1) | CA2630202C (es) |
| CY (1) | CY1112031T1 (es) |
| DE (1) | DE102005055354A1 (es) |
| DK (1) | DK1951697T3 (es) |
| EA (1) | EA015352B1 (es) |
| ES (1) | ES2368001T3 (es) |
| IL (1) | IL191360A (es) |
| PL (1) | PL1951697T3 (es) |
| PT (1) | PT1951697E (es) |
| SI (1) | SI1951697T1 (es) |
| WO (1) | WO2007057092A1 (es) |
| ZA (1) | ZA200805406B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005055355A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007026341A1 (de) * | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007041115A1 (de) * | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | Thiadiazinonderivate |
| DE102007061963A1 (de) * | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008062826A1 (de) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009003975A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Benzothiazolonderivate |
| RU2458060C2 (ru) * | 2009-05-22 | 2012-08-10 | Государственное образовательное учреждение высшего профессионального образования "Уральский государственный технический университет - УПИ имени первого Президента России Б.Н. Ельцина" | 5-(4'-гидроксифенил)- и 5-(2',5'-дигидроксифенил)-6н-1,3,4-тиадиазин-2-амины, гидрогалагениды, ингибирующие агрегацию тромбоцитов при внутривенном введении |
| CN111454232B (zh) * | 2020-05-30 | 2021-11-23 | 南方医科大学 | 一种1,3,4-噻二嗪类化合物及其应用 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19502699A1 (de) * | 1995-01-28 | 1996-08-01 | Merck Patent Gmbh | Arylalkyl-thiadiazinone |
| DE19533975A1 (de) * | 1995-09-14 | 1997-03-20 | Merck Patent Gmbh | Arylalkyl-diazinone |
| GB9525262D0 (en) * | 1995-12-11 | 1996-02-07 | Bayer Ag | Heterocyclylcarbonyl substituted benzofuranyl-ureas |
| DE19604388A1 (de) * | 1996-02-07 | 1997-08-14 | Merck Patent Gmbh | Arylalkyl-diazinone |
| CA2382789A1 (en) | 1999-08-27 | 2001-03-08 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
| DE10150517A1 (de) * | 2001-10-12 | 2003-04-17 | Merck Patent Gmbh | Verwendung von Phosphodiesterase IV-Inhibitoren |
| SK1862004A3 (en) | 2001-10-31 | 2004-08-03 | Type 4 phosphodiesterase inhibitors and uses thereof | |
| KR100915287B1 (ko) * | 2001-12-11 | 2009-09-03 | 교와 핫꼬 기린 가부시키가이샤 | 티아디아졸린 유도체 |
| DE102005055355A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
-
2005
- 2005-11-21 DE DE102005055354A patent/DE102005055354A1/de not_active Withdrawn
-
2006
- 2006-10-25 PT PT06806537T patent/PT1951697E/pt unknown
- 2006-10-25 AT AT06806537T patent/ATE517878T1/de active
- 2006-10-25 JP JP2008540479A patent/JP5334586B2/ja not_active Expired - Fee Related
- 2006-10-25 WO PCT/EP2006/010285 patent/WO2007057092A1/de active Application Filing
- 2006-10-25 CA CA2630202A patent/CA2630202C/en not_active Expired - Fee Related
- 2006-10-25 US US12/094,542 patent/US7902186B2/en not_active Expired - Fee Related
- 2006-10-25 ES ES06806537T patent/ES2368001T3/es active Active
- 2006-10-25 BR BRPI0618806-0A patent/BRPI0618806A2/pt not_active Application Discontinuation
- 2006-10-25 EP EP06806537A patent/EP1951697B1/de active Active
- 2006-10-25 PL PL06806537T patent/PL1951697T3/pl unknown
- 2006-10-25 DK DK06806537.4T patent/DK1951697T3/da active
- 2006-10-25 CN CNA2006800434108A patent/CN101312956A/zh active Pending
- 2006-10-25 AU AU2006314873A patent/AU2006314873B2/en not_active Ceased
- 2006-10-25 SI SI200631094T patent/SI1951697T1/sl unknown
- 2006-10-25 EA EA200801365A patent/EA015352B1/ru not_active IP Right Cessation
- 2006-10-25 KR KR1020087014967A patent/KR101424825B1/ko active IP Right Grant
- 2006-11-21 AR ARP060105082A patent/AR058205A1/es not_active Application Discontinuation
-
2008
- 2008-05-12 IL IL191360A patent/IL191360A/en not_active IP Right Cessation
- 2008-06-20 ZA ZA200805406A patent/ZA200805406B/xx unknown
-
2011
- 2011-10-27 CY CY20111101025T patent/CY1112031T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1951697T3 (da) | 2011-09-26 |
| KR101424825B1 (ko) | 2014-08-01 |
| EA200801365A1 (ru) | 2008-10-30 |
| US7902186B2 (en) | 2011-03-08 |
| ATE517878T1 (de) | 2011-08-15 |
| EP1951697B1 (de) | 2011-07-27 |
| CA2630202C (en) | 2015-03-31 |
| SI1951697T1 (sl) | 2011-09-30 |
| ZA200805406B (en) | 2009-11-25 |
| PT1951697E (pt) | 2011-11-04 |
| AU2006314873B2 (en) | 2011-12-08 |
| DE102005055354A1 (de) | 2007-10-31 |
| CN101312956A (zh) | 2008-11-26 |
| JP2009516657A (ja) | 2009-04-23 |
| IL191360A (en) | 2013-10-31 |
| WO2007057092A1 (de) | 2007-05-24 |
| US20080318936A1 (en) | 2008-12-25 |
| EA015352B1 (ru) | 2011-06-30 |
| KR20080070763A (ko) | 2008-07-30 |
| CY1112031T1 (el) | 2015-11-04 |
| BRPI0618806A2 (pt) | 2011-09-13 |
| ES2368001T3 (es) | 2011-11-11 |
| JP5334586B2 (ja) | 2013-11-06 |
| EP1951697A1 (de) | 2008-08-06 |
| AU2006314873A1 (en) | 2007-05-24 |
| PL1951697T3 (pl) | 2011-11-30 |
| CA2630202A1 (en) | 2007-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058205A1 (es) | 5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4] tiadiazinas sustituidas | |
| AR057899A1 (es) | Derivados de 3,6-dihidro-2-oxo-6h-[1,3,4]tiadiazina, metodo de preparacion, composiciones farmaceuticas que los contienen y usos en la terapia contra el cancer | |
| AR055376A1 (es) | Derivados de 1-acildihidropirazol | |
| AR061574A1 (es) | Derivados de 3- amino- imidazo [1,2-a] piridina | |
| AR063266A1 (es) | Derivados de 3- amino- imidazo [1,2-a] piridina | |
| AR066543A1 (es) | Derivados de piridazinona | |
| AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| AR051623A1 (es) | Derivados de piridopirimidinona | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| AR068659A1 (es) | Derivados de imidazol inhibidores de autotaxina | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR068657A1 (es) | Derivados de piperidina y piperazina | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| CO6241076A2 (es) | Compuestos de benzamida y aplicaciones de los mismos | |
| AR082722A1 (es) | Derivados de pirimidina | |
| AR072798A1 (es) | Derivados de pirido-piridinonas, su preparacion, composicion farmaceutica y su uso en el tratamiento de las enfermedades ligadas a la actividad de la proteina quinasa | |
| AR054047A1 (es) | Derivados de fenilquinazolina | |
| AR056310A1 (es) | Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos | |
| AR072192A1 (es) | Derivados de tiazolil-piperidina | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |